Drug
PEGPH20 clinical trials
Also written PEGPH20 and pegvorhyaluronidase alfa.
- studies test it
- 16
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- PEGPH20
- 16
Other names
Studies by the year they started
16 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Halozyme Therapeutics (7) · Memorial Sloan Kettering Cancer Center (2) · Hoffmann-La Roche (1) · SWOG Cancer Research Network (1) · Gulam Manji (1) · Andrew Ko (1) · Pancreatic Cancer Research Team (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Albumin-Bound Paclitaxel (3) · Paclitaxel (3) · Pembrolizumab (3) · Gemcitabine (2) · Atezolizumab (2) · Cobimetinib (1) · Motixafortide (1) · Selicrelumab (1)
Studies
Open first, then newest update. How each study uses PEGPH20 is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic AdenocarcinomaActive, not recruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT02921022Written as PEGPH20
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Written as PEGPH20
- S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic CancerCompletedPhase 1/2SWOG Cancer Research NetworkNCT01959139Written as PEGPH20
- Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal AdenocarcinomaTerminatedPhase 2Gulam ManjiNCT03979066Written as PEGPH20
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerCompletedPhase 2Halozyme TherapeuticsNCT01839487Written as PEGPH20
- Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic CancerWithdrawnPhase 2M.D. Anderson Cancer CenterNCT04058964Written as Pegylated Recombinant Human Hyaluronidase PH20
- A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsCompletedPhase 1Halozyme TherapeuticsNCT02563548Written as PEGPH20
- Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaTerminatedPhase 1Halozyme TherapeuticsNCT03267940Written as PEGPH20
- MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal AdenocarcinomaWithdrawnPhase 2Abramson Cancer Center at Penn MedicineNCT04134468Written as Pegvorhyaluronidase alfa
- PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal AdenocarcinomaTerminatedPhase 2Andrew KoNCT02487277Written as PEGPH20
- Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDACStatus unknownPhase 2Pancreatic Cancer Research TeamNCT03634332Written as PEGPH20
- A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCTerminatedPhase 1Halozyme TherapeuticsNCT02346370Written as PEGylated recombinant human hyaluronidase PH20
- Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic CancerCompletedPhase 1/2Halozyme TherapeuticsNCT01453153Written as PEGPH20
- Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical ResectionCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT02241187Written as PEGPH20
- Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid TumorsCompletedPhase 1Halozyme TherapeuticsNCT01170897Written as PEGPH20
- Safety Study of PEGPH20 Given to Patients With Advanced Solid TumorsCompletedPhase 1Halozyme TherapeuticsNCT00834704Written as PEGPH20